First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    InspireMD Inc. (NSPR): the developments shaping its investment case

    Follow the evidence affecting InspireMD Inc.'s demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research InspireMD Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-21 · 2 reports
    InspireMD Announces Amendments to Series J and Series K Warrants for Potential $11 Million Proceeds
    Channel: Direct capital raise, potential dilution, and financing certainty tied to product approval.
    mixed· 1-3m
    2026-08-17
    InspireMD, Inc. Initiates $9 Million Annualized Cost Savings Program
    Channel: Direct cost reduction leading to improved profitability and cash flow.
    Bullish· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-09-21net_debtBearishLiability-management transactions often reduce gross debt or push maturities out.
    2026-09-21interest_expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.
    2026-07-02share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-07-02net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-07-02revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    3 events mapped to NSPR since 2026-08-17. Evidence through 2026-09-21.

    DateEventChannelDirectionHorizonImpact
    2026-09-21InspireMD Announces Amendments to Series J and Series K Warrants for Potential $11 Million ProceedsDirect capital raise, potential dilution, and financing certainty tied to product approval.mixed1-3m0.70
    2026-09-21InspireMD Announces Amendments to Series J and Series K WarrantsThe amendment of warrants to align with a key regulatory milestone (FDA approval) suggests a strategic move to secure funding upon a positive catalyst. This could provide capital for operations and commercialization, but also implies potential dilution.mixed3-12m0.70
    2026-08-17InspireMD, Inc. Initiates $9 Million Annualized Cost Savings ProgramDirect cost reduction leading to improved profitability and cash flow.Bullish3-12m0.70

    Continue this research

    Build your InspireMD Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the NSPR entity page →

    Research InspireMD Inc. · $399/mo